Abstract
High throughput screening of the Roche compound collection led to the identification of diaminopyrroloquinazoline series as a novel class of PTP1B inhibitors. Structural modification of diaminopyrroloquinazoline series resulted in pyrido[2,3-d]pyrimidine-2,4-diamine series which was further optimized to give compounds 5 and 24 as potent, selective (except T-cell phosphatase) PTP1B inhibitors with good mouse PK properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Diamines / chemical synthesis
-
Diamines / chemistry
-
Diamines / pharmacology*
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Mice
-
Mice, Inbred C57BL
-
Molecular Structure
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors*
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Structure-Activity Relationship
Substances
-
7-phenyl-pyrido(2,3-d)pyrimidine-2,4-diamine
-
Diamines
-
Enzyme Inhibitors
-
Pyrimidines
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1